After 48 weeks of treatment, retatrutide demonstrated dose-dependent weight loss: 12 mg dose achieved 24.2% body weight reduction , the highest ever reported in a Phase 2 obesity trial
Rev Endocr Metab Disord (2025) doi:10.1007/s11154-025-09967-4
Blher, M., Rosenstock, J., Hoefler, J., et al
[1] [2] Routine consultation with a healthcare provider is appropriate when: Bloating persists beyond 2-3 weeks despite dietary modifications and dose stabilization Symptoms significantly impair quality of life or daily functioning Bloating is accompanied by persistent nausea, early satiety, or regurgitation, which may suggest severe gastroparesis New or worsening heartburn or reflux symptoms develop There is concern about medication interactions or the need for dose adjustment Healthcare providers should evaluate for potential complications of tirzepatide therapy, including acute pancreatitis (characterized by severe epigastric pain radiating to the back, nausea, and elevated lipase levels) and severe gastroparesis

7 Instead, initial treatment should involve replacing the natural oils of the tear film with lipid-containing over-the-counter lubricant eyedrops, which may restore the balance of the tear film and provide both symptomatic relief and improvement in clinical signs of MGD and EDE with long-term use